ANX Financial Facts

Loss from operations: -5.72M
Net loss applicable to common stock: -5.7M
See Full Income Statement

Cash and cash equivalents: -70.93M
Total current liabilities: 4.83M
See Full Balance Sheet

Adventrx Pharmaceuticals, Inc. (ANX) Earnings

  |   Expand Research on ANX
Next EPS Date N/A EPS Growth Rate +46.2% *Last Qtr.
Average EPS % Beat Rate +25.0% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -24.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
11/5/12 Q312 -$0.07N/A N/A N/AN/A N/A 0% Details
8/6/12 Q212 $0.09N/A N/A N/AN/A N/A 0% Details
5/7/12 Q112 -$0.09N/A N/A N/AN/A N/A 0% Details
3/7/12 Q411 -$0.06-$0.09 +$0.03N/AN/A N/A 0% Details
11/7/11 Q311 -$0.13-$0.13 $0.00N/AN/A N/A -29.8% Details
5/9/11 Q111 -$0.13-$0.26 +$0.13N/AN/A N/A -71.6% Details
3/10/11 Q410 -$0.15-$0.18 +$0.03N/AN/A N/A -64.6% Details